NEWTON, Mass.--(BUSINESS WIRE)--Tryton Medical, Inc., a leading developer of stents designed to treat bifurcation lesions, announced the successful completion of the Company’s first ten clinical cases. Patients with coronary blockages involving a side branch were successfully treated using the firm’s Side-Branch Stent(TM) without in-hospital complications. Approximately 540,000 procedures are performed every year to address bifurcation lesions, accounting for 20% of all coronary lesions treated. Despite the significant number of bifurcation lesions, no dedicated solution exists today that fully addresses these lesions. Patients currently undergo complex procedures which are unpredictable and often lead to suboptimal results, with greatly increased risk for thrombosis (i.e., early, subacute and delayed) as well as restenosis. Tryton Medical, Inc. initiated a multi-center clinical trial to demonstrate the clinical feasibility of the Tryton Side-Branch Stent to treat Coronary Bifurcation Lesions. The patients were treated by Professor Eberhard Grube, M.D. and Dr. Ralf Muller from the HELIOS Heart Center Siegburg, Germany.
“The Tryton Side-Branch Stent was used in conjunction with a standard workhorse stent to treat a wide spectrum of complex bifurcation lesions, all with excellent angiographic results and without any major adverse cardiac events,” said Professor Eberhard Grube, Chief of Cardiology/Angiology, HELIOS Heart Center Siegburg, Germany. “Tryton’s dedicated ‘save-the-side-branch’ strategy removes the uncertainty associated with provisional stenting,” Professor Grube added. To see pictures of pre and post-angiographic results that show the Tryton Side-Branch Stent benefits, visit www.TrytonMedical.com
“We are pleased with how seamlessly the Tryton strategy has been incorporated into routine practice to treat challenging bifurcation lesions all via 6 French guides,” said Dr. Aaron Kaplan, Inventor of the Tryton Stent and Associate Professor from the Dartmouth-Hitchcock Medial Center, New Hampshire. “These cases demonstrate the clinical feasibility of Tryton’s technology,” Dr. Kaplan added.
“The Tryton Side-Branch Stent is a unique, high performance, balloon-expandable, 5 French guide compatible system that tracks over a single wire. When used in conjunction with any existing standard coronary stent for the main vessel, it provides superior coverage and radial strength to the origin of the side branch,” said Richard Davis, CTO, Tryton Medical, Inc.
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent-- leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
Tryton Medical’s Side-Branch Stent(TM) has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact Joe Romano, Partner, HighGround, Inc. at +1 781-279-1320 x 208, jromano@highgroundinc.com or visit www.TrytonMedical.com
Contact:
HighGround, Inc. Joe Romano, 781-279-1320 x 208 Partner jromano@highgroundinc.com
Source: HighGround, Inc.
